Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.

Leone, Valentina Fanny; Imeraj, Amantia; Gastoldi, Sara; Mele, Caterina; Liguori, Lucia; Condemi, Carmelita; Ruggenenti, Piero; Remuzzi, Giuseppe; Carrara, Camillo.

Afiliação

Leone VF; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Imeraj A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Gastoldi S; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Mele C; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Liguori L; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Condemi C; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Ruggenenti P; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Carrara C; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Front Pharmacol ; 13: 842473, 2022.

Article em En | MEDLINE | ID: mdl-35295324

Palavras-chave

coronavirus disease 2019 (COVID-19); eculizumab; hemolytic uremic syndrome; severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2); thrombotic microangiopathy

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article